 | |
| Clinical data | |
|---|---|
| Trade names | Terlivaz |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | ~30% |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.035.149 |
| Chemical and physical data | |
| Formula | C52H74N16O15S2 |
| Molar mass | 1227.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Terlipressin, sold under the brand nameTerlivaz among others, is ananalogue ofvasopressin used as a vasoactivedrug in the management oflow blood pressure. It has been found to be effective whennorepinephrine does not help. Terlipressin is a vasopressin receptor agonist.[1]
Terlipressin was approved for medical use in the United States in 2022.[1][3][4] The USFood and Drug Administration (FDA) considers it to be afirst-in-class medication.[4][5]
Terlipressin isindicated to improve kidney function in adults withhepatorenal syndrome with rapid reduction in kidney function.[1]
Indications for use include norepinephrine-resistantseptic shock[6] although, 2021 Surviving Sepsis Guidelines recommend against its use for adults with septic shock[7] andhepatorenal syndrome.[8] In addition, it is used to treat bleedingesophageal varices.[9]
Terlipressin is contraindicated in people experiencing hypoxia or worsening respiratory symptoms and in people with ongoing coronary, peripheral or mesenteric ischemia.[1] Terlipressin may cause fetal harm when used during pregnancy.[1]
Terlipressin is available in United States,[10] New Zealand,[11] Australia, the European Union,[12] India, Indonesia, Pakistan, UAE. It is sold under various brand names including Glypressin and Terlivaz.
This article incorporates text from this source, which is in thepublic domain. This article incorporates text from this source, which is in thepublic domain.
